Trastuzumab and T-DXd are effective in HER2-positive gastric and GEJ cancers, moving towards earlier intervention stages. A meta-analysis of T-DXd showed significant efficacy and manageable safety in ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ Ziihera. Or at least that appears to be the consensus following ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...

This discussion reviews the ongoing HERIZON-GEA-01 trial, a global Phase 3 study evaluating zanidatamab as part of first-line therapy for HER2-positive gastric and gastroesophageal junction (GEJ) ...

Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and safety of ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan improved invasive DFS by 53% vs. T-DM1 for patients with residual disease after ...

Treatment with T-DXd resulted in a statistically significant and clinically meaningful improvement in IDFS vs T-DM1. Topline results were announced from a phase 3 trial comparing fam-trastuzumab ...

Eribulin (Halaven) proved non-inferior to a taxane when added to trastuzumab-pertuzumab (HP) as first-line systemic treatment for patients with locally advanced/metastatic HER2+ breast cancer, ...

Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the ...

AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2-associated metastatic HER2-negative breast cancer (BC). This is an ASCO Meeting Abstract from the 2025 ASCO ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer. Now, the company can further back up the regimen’s prowess with a ...